GlobalData on MSN18h
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...
News Medical on MSN1d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
3d
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback